PSP Sponsor Reporting in Saudi Arabia: Definitions, Denominators and Dashboard Examples
A three-layer PSP reporting framework — operational, pharmacovigilance, and commercial — with denominator definitions and metric governance guidance for Saudi pharma teams.
A three-layer reporting framework — operational, pharmacovigilance, and commercial — with denominator definitions for Saudi PSP sponsor reports.
On this page
PSP Sponsor Reporting in Saudi Arabia: Definitions, Denominators and Dashboard Examples
Sponsor reporting in Saudi patient support programs is where most program governance problems become visible — and where most are quietly hidden. A well-structured report tells the sponsor team what the program is actually doing, identifies what is working and what needs attention, and creates the audit trail that protects everyone if a pharmacovigilance question is raised. A poorly structured report conceals performance problems behind undefined metrics, shifting denominators, and activity counts presented as outcomes.
This article defines the standard metric families for Saudi PSP sponsor reporting, explains how denominators determine what a metric actually measures, and describes what a well-structured monthly dashboard includes.
Key Takeaways
- Saudi PSP sponsor reports should cover three metric layers: program health (operational), safety compliance (pharmacovigilance), and commercial performance — each reported against pre-defined targets.
- The most damaging reporting problems in Saudi PSPs are not data quality failures — they are definition inconsistencies that make trend analysis impossible across reporting periods.
- A metric without a defined denominator is not a metric. "Activation: 847" means nothing; "Activation rate: 847/1,124 referred patients = 75.4%" is a metric.
- Keywords are unvalidated editorial hypotheses (H); no search volume claims are made.
Why Sponsor Reporting Fails in Saudi PSPs
The failure mode in Saudi PSP reporting is usually not technical — it is structural. Reports fail when:
Metrics are defined by what the platform can measure, not what the sponsor needs to know. A platform that tracks contact volume easily reports contact volume. If contact volume is what the sponsor team actually needs — a count of calls made — this is fine. If contact volume is being used as a proxy for patient engagement, it is a category error that the report format is encoding into the program's performance picture.
Denominators shift between reporting periods without documentation. If the activation rate in January is calculated as (activated patients / enrolled patients in the previous 90 days) and in February shifts to (activated patients / total enrolled patients to date), the January and February numbers cannot be compared — but they will be, because nothing in the report signals that the denominator changed.
Pharmacovigilance metrics are absent from sponsor reports entirely. Many Saudi PSP sponsor reports cover enrollment, contacts, and satisfaction metrics — sometimes with therapy adherence estimates — but do not report AE capture rates, escalation timeliness, or reconciliation status. This means the sponsor's commercial and medical affairs teams are reviewing a report that tells them nothing about the program's compliance status.
Targets are not set before the reporting period begins. A report that shows enrollment of 847 without a target is not a performance report — it is a count. Performance emerges from comparison against expectation, and expectations need to be defined before the measurement period, not adjusted to match the number that came in.
The Three-Layer Report Architecture
Layer 1: Program Health (Operational)
The operational layer reports on the program's ability to enroll, activate, and retain patients — the indicators that signal whether the program is functioning as designed.
Standard operational metrics:
| Metric | Definition | Denominator |
|---|---|---|
| Referral-to-enrollment rate | Patients completing enrollment / referred patients | HCP-referred patients in period |
| Time to enrollment | Days from referral to enrollment completion | Per-patient, reported as median |
| Enrollment completion rate by step | Patients completing each step / patients starting that step | Patients reaching each enrollment step |
| Activation rate | Patients completing first meaningful contact / enrolled patients | Enrolled patients, excluding formal withdrawals |
| Time to activation | Days from enrollment to first meaningful contact | Per-patient, reported as median |
| Monthly retention rate | Patients with ≥1 meaningful contact in period / expected active patients | Enrolled patients minus formal discontinuations and withdrawals |
| 90-day retention | Patients active at 90 days / patients enrolled in cohort | Cohort defined as patients enrolled in [period] |
| Lapse rate | Patients with no contact for >[threshold] days / expected active patients | Expected active patients at start of period |
Defining "meaningful contact": A meaningful contact is a completed interaction that includes substantive clinical or program content — not a voicemail, an unanswered call, or a push notification delivered. The definition must be fixed for the duration of the program and documented in the reporting methodology section of every report.
Layer 2: Safety Compliance (Pharmacovigilance)
The pharmacovigilance layer reports on the program's performance as a pharmacovigilance instrument. This layer is mandatory for every Saudi PSP report and must be reviewed by or with the sponsor's pharmacovigilance team.
Standard pharmacovigilance metrics: [HOLD — expert review: specific PV metrics and benchmarks require PV professional review]
| Metric | Definition | Denominator |
|---|---|---|
| AE capture rate | Patient interactions completing structured AE prompt / total meaningful patient interactions | Meaningful patient interactions completed in period |
| Serious AE escalation timeliness | Serious AEs escalated within SDEA timeframe / total serious AEs captured | Serious AEs captured in period |
| AE minimum dataset completeness | AE reports with all 4 minimum valid data elements / total AE reports captured | AE reports captured in period |
| Reconciliation completion rate | Reconciliation cycles completed on schedule / total reconciliation cycles due | Reconciliation cycles due per SDEA schedule |
| SDEA compliance status | Current SDEA in place and signed by all parties (Y/N) | N/A — binary status |
Reporting the pharmacovigilance layer: The PV layer should be a standing agenda item in monthly sponsor-operator review meetings. The PV data should be reviewed by the sponsor's designated safety contact, not only by the commercial or brand team. Any AE escalation timeliness result below 100% should trigger a documented investigation.
Layer 3: Commercial Performance
The commercial layer reports on the program's business performance — HCP participation, program reach relative to market, and trend data. This layer answers the brand team's question: is the program creating the patient coverage and commercial support we designed it for?
Standard commercial metrics:
| Metric | Definition | Denominator |
|---|---|---|
| HCP participation rate | HCPs who have referred ≥1 patient in period / total target HCPs in program territory | Target HCP list (defined and static for the reporting period) |
| New HCP referral rate | HCPs making first referral in period / total target HCPs | Target HCPs who have not previously referred |
| Program reach | Enrolled patients / estimated eligible patients in market | Estimated eligible patient population (requires market data) |
| Patient: HCP ratio | Enrolled patients / participating HCPs | HCPs with active referred patients |
Note on market reach denominators: Estimating eligible patient populations in Saudi Arabia requires market data sources (pharmacy sales data, prescription audit data, disease incidence estimates). These denominators are estimates, not exact figures, and should be labeled as such in every report. Using an undefined or shifting denominator for market reach calculations is a frequent source of misleading performance pictures. [VERIFY WITH BRAND — specific market data sources and denominator approaches require commercial and medical affairs validation]
Report Format and Governance
Monthly report components:
- Executive summary: One page. Current enrollment, activation, and retention vs. target. PV compliance status. Any flags requiring sponsor action.
- Operational metrics table: All Layer 1 metrics with current period values, prior period values, and targets.
- Pharmacovigilance metrics table: All Layer 2 metrics. Any below-target results with documented investigation status.
- Commercial metrics table: Layer 3 metrics with trend data.
- Metric definitions annex: Fixed definitions for all metrics including exact denominator specifications. This annex should be unchanged from month to month unless a formal definition revision is documented and approved.
- Open items log: Actions required from sponsor and operator, with owners and due dates.
What a report should not contain:
- Metric names without definitions
- Numbers without denominators or units
- Trend charts covering periods where the metric definition changed without annotation
- Satisfaction scores presented as clinical outcomes
- Activity counts (calls made, messages sent) presented as engagement metrics without a connected outcome measure
FAQ
How often should sponsor reports be delivered? Monthly reporting is the standard for operational and commercial metrics. Pharmacovigilance reconciliation reports should be delivered on the SDEA-defined schedule (typically monthly or bi-weekly for high-volume programs). Serious AE escalation is reported immediately at the event level, not in periodic reports. [VERIFY WITH BRAND — specific reporting cadence should reflect SDEA terms and SLA requirements]
Who should receive PSP sponsor reports? The brand team and commercial lead should receive the full report. The pharmacovigilance layer should be shared directly with the sponsor's designated safety contact and reviewed by the safety team. Medical affairs should receive reports covering patient interaction content and therapy support metrics. Not everyone needs the full report; routing the PV layer only to commercial recipients is a governance gap. [VERIFY WITH BRAND — specific report distribution should reflect sponsor organizational structure]
How should we handle metric definition changes mid-program? Any change to a metric definition — including denominator changes — must be documented in writing, approved by both sponsor and operator, and reflected in all historical reporting with clear annotation of the change date. Report series that contain un-annotated definition changes cannot be used for trend analysis and should not be used in sponsor or regulatory submissions.
What is the minimum viable PSP report for a Saudi program? At minimum: enrollment count with denominator, activation rate with denominator, monthly retention rate with denominator, AE capture rate with denominator, and SDEA compliance status. Any report that omits the AE capture rate is missing its most important compliance indicator. [HOLD — expert review: specific minimum reporting requirements require PV professional guidance]
How do we validate that the numbers in operator reports are accurate? Periodic data audits — comparing platform data exports against operator-reported summaries — are the standard mechanism for validating report accuracy. Audits should be specified in the operator contract as a sponsor right exercisable at defined intervals. Data discrepancies identified in audits should be documented and resolved, with root cause identified, within a contractually defined timeframe. [VERIFY WITH BRAND — specific audit rights and processes should be defined in the operator contract]
Published: 2026-11-05 · Author: CareSync Team · This article provides general guidance on sponsor reporting practices for patient support programs in Saudi Arabia. It does not constitute legal, regulatory, or medical advice. All reporting frameworks and pharmacovigilance metric requirements should be designed with qualified advisors and reviewed against SDEA terms and current SFDA guidance.
Review your PSP sponsor reporting framework with CareSync. Request a reporting design consultation →
Need a structured PSP reporting framework?
Request a reporting consultation